• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

RFA joins arsenal for breast cancer metastases in the liver

Article

In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.

In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.

Researchers from 12 centers participating in the tumor radio-frequency ablation Italian network (TRAIN) treated 102 patients with breast cancer, using the ablation technique. Under ultrasound or CT guidance, they applied RFA to tumors ranging from 0.8 to 5 cm in diameter. Results were presented at the 2004 RSNA meeting.

Using the Kaplan-Meier method, the researchers reported survival rates ranging from 95.2% at one year to 29.8% at five years. They completed RFA of tumors in 91.2% of the patients after 121 treatment sessions, and the primary effectiveness rate on a lesion-by-lesion basis was 86.9.

Recent Videos
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.